submit to the journals

Future of Radiotherapy Delivery in Rectal Cancer— European and US Approaches

Oncology & Hematology Review, 2014;10(2):139–43 DOI: http://doi.org/10.17925/OHR.2014.10.2.139

Abstract:

Neoadjuvant radiation therapy is integral in the management of patients with localized rectal cancer. In parts of Europe, patients with operable rectal cancer are treated with short-course radiation therapy delivered in five daily, 5 Gy fractions to a total dose of 25 Gy, followed by surgery within 1 week. In the US, the standard for locally advanced rectal cancer is neoadjuvant chemoradiotherapy. This approach is principally based on the results of the German Rectal Cancer Study Group trial evaluating preoperative compared with postoperative chemoradiation. Surgery is typically performed at 4–8 weeks following completion of long-course chemoradiotherapy, facilitating tumor downstaging, and potential sphincter sparing surgery. No significant difference in clinical outcomes has been observed between these two approaches in two randomized clinical trials; however, further follow-up of these studies and new results from ongoing trials are anticipated to further clarify the optimal neoadjuvant treatment strategy.

Keywords: Rectal cancer, radiation therapy, short course, long course, chemoradiation, neoadjuvant therapy
Disclosure: Jordan A Torok, MD, Brian G Czito, MD, Christopher G Willett, MD, and Manisha Palta, MD, have no conflicts of interest to disclose. No funding was received in the publication of this article.
Received: July 31, 2014 Accepted: November 02, 2014
Correspondence: Manisha Palta, MD, Department of Radiation Oncology, Duke University, DUMC 3085 Durham, NC 27710, US. E: manisha.palta@dm.duke.edu

Over the past several decades, two paradigms have emerged in the preoperative treatment of rectal cancer: a short course of radiation therapy (RT) often utilized in centers across Northern Europe and longcourse chemoradiation (CRT) in other parts of Europe and the US. The short-course technique was validated by randomized trials comparing this technique to surgery alone. The majority of these trials included patients with resectable, nonmetastatic rectal cancer, both early and advanced stages, with surgery 1 week following treatment completion. By contrast, long-course therapy is typically offered to patients with more advanced disease (cT3-4, N+) to improve local control, R0 resection rates, and potentially increase rates of sphincter-preserving surgery. Randomized studies have compared long-course CRT followed by surgery to upfront surgery and postoperative CRT. Multiple studies have attempted to optimize the long-course CRT platform with the addition of oxaliplatin. Two randomized trials have compared short-course RT to long-course CRT; however, significant debate still exists regarding the optimal neoadjuvant approach in patients with rectal cancer.

Short-course Radiotherapy
In early trials of preoperative short-course RT from Sweden, patients were randomized to preoperative RT (25 Gy in five daily fractions over 5–7 days) or underwent surgery alone. The incidence of pelvic recurrence was significantly reduced with RT at the expense of increased postoperative morbidity.1,2 A similar follow-up trial with improved RT techniques showed reduction in both locoregional and distant recurrence as well as improvement in overall survival (OS) with the short-course regimen.3 The rate of postoperative morbidity was reduced with the improved RT technique and postoperative mortality was low in both groups. These trials set the stage for the Swedish Rectal Cancer Trial, which randomized patients to the short-course regimen followed by surgery 1 week later versus surgery alone. After a median follow-up of 13 years, RT significantly reduced local recurrence (LR) rates (9 versus 26 %; p<0.001) and improved OS (38 versus 30 %; p=0.008).4 Subset analyses found statistically significant reductions in LR for all stage groups. However, these LR and OS benefits were not without potential toxicity. With long-term follow-up, patients treated with RT were more likely to develop small bowel obstruction.5,6

The Swedish Rectal Cancer Trial was undertaken prior to widespread adoption of the total mesorectal excision (TME) surgical technique. Compared with the conventional surgical techniques at that time, TME significantly reduced LR rates.7 To determine the value of preoperative RT in the TME era, investigators from The Netherlands initiated a multicenter trial randomizing 1,861 patients to preoperative short-course RT with TME compared with TME alone. The RT dose/fractionation and surgical timelines were similar to the Swedish trials. The most recent update with median follow-up of 12 years demonstrated a persistent reduction in the 10-year cumulative incidence of LR (5 versus 11 %; p<0.0001).8 Compared to the Swedish Rectal Cancer Trial, overall LR rates were substantially lower with TME. The 10-year risk of LR with TME alone for stage I and III rectal cancers was 3 % and 19 %, respectively. While there was no improvement in 10-year OS with RT (48 versus 49 %; p=0.86), OS was improved in stage III patients with negative circumferential radial margins (50 versus 40 %; p=0.03). The benefit in local control was at the expense of impaired bowel function and incontinence.9

References:
  1. Stockholm Rectal Cancer Study Group, Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial, Cancer, 1990;66:49–55.
  2. Cedermark B, Johansson H, Rutqvist LE, Wilking N, The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group, Cancer, 1995;75:2269–75.
  3. Stockholm Colorectal Cancer Study Group, Randomized study on preoperative radiotherapy in rectal carcinoma, Ann Surg Oncol, 1996;3:423–30.
  4. Folkesson J, Birgisson H, Pahlman L, et al., Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate, J Clin Oncol, 2005;23:5644–50.
  5. Birgisson H, Pahlman L, Gunnarsson U, et al., Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial, J Clin Oncol, 2005;23:8697–705.
  6. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B, Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy, Br J Surg, 2008;95:206–13.
  7. Carlsen E, Schlichting E, Guldvog I, et al., Effect of the introduction of total mesorectal excision for the treatment of rectal cancer, Br J Surg, 1998;85:526–9.
  8. van Gijn W, Marijnen CAM, Nagtegaal ID, et al., Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial, Lancet Oncol, 2011;12:575–82.
  9. Peeters KC, van de Velde CJ, Leer JW, et al., Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study, J Clin Oncol, 2005;23:6199–206.
  10. Sebag-Montefiore D, Stephens RJ, Steele R, et al., Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial, Lancet, 2009;373:811–20.
  11. Sauer R, Becker H, Hohenberger W, et al., Preoperative versus postoperative chemoradiotherapy for rectal cancer, N Engl J Med, 2004;351:1731–1740.
  12. Sauer R, Liersch T, Merkel S, et al., Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years, J Clin Oncol, 2012;30:1926–33.
  13. Roh MS, Colangelo LH, O’Connell MJ, et al., Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03, J Clin Oncol, 2009;27:5124–30.
  14. Park JH, Yoon SM, Yu CS, et al., Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer, Cancer, 2011;117:3703–12.
  15. Bosset JF, Calais G, Mineur L, et al., Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921, J Clin Oncol, 2005;23:5620–7.
  16. Bosset JF, Calais G, Mineur L, et al., Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study, Lancet Oncol, 2014;15:184–90.
  17. Gerard JP, Conroy T, Bonnetain F, et al., Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203, J Clin Oncol, 2006;24:4620–5.
  18. Braendengen M, Tveit KM, Berglund A, et al., Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer, J Clin Oncol, 2008;26:3687–94.
  19. O’Connell MJ, Martenson JA, Wieand HS, et al., Improving adjuvant therapy for rectal cancer by combining protractedinfusion fluorouracil with radiation therapy after curative surgery, N Engl J Med, 1994;331:502–7.
  20. Hofheinz R-D, Wenz F, Post S, et al., Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial, Lancet Oncol, 2012;13:579–88.
  21. O’Connell MJ, Colangelo LH, Beart RW, et al., Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project Trial R-04, J Clin Oncol, 2014;32:1927–34.
  22. Rodel C, Liersch T, Becker H, et al., Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/ AIO-04 randomised phase 3 trial, Lancet Oncol, 2012;13:679–87.
  23. Aschele C, Cionini L, Lonardi S, et al., Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR- 01 randomized phase III trial, J Clin Oncol, 2011;29:2773–80.
  24. Gerard JP, Azria D, Gourgou-Bourgade S, et al., Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2, J Clin Oncol, 2010;28:1638–44.
  25. Gerard JP, Azria D, Gourgou-Bourgade S, et al., Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer, J Clin Oncol, 2012;30:4558–65.
  26. Rodel C, Liersch T, Fietkau R, et al., Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial, J Clin Oncol, 2014;32:(Suppl. 15); abstr 3500.
  27. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al., Longterm results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer, Br J Surg, 2006;93:1215–23.
  28. Ngan SY, Burmeister B, Fisher RJ, et al., Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04, J Clin Oncol, 2012;30:3827–33.
  29. Pettersson D, Cedermark B, Holm T, et al., Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer, Br J Surg, 2010;97:580–7.
  30. Nilsson PJ, van Etten B, Hospers GA, et al., Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer—the RAPIDO trial, BMC Cancer, 2013;13:279.
  31. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC, Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy?, Dis Colon Rectum, 1999;42:167–73.
  32. Guillem JG, Diaz-Gonzalez JA, Minsky BD, et al., cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted, J Clin Oncol, 2008;26:368–73.
  33. Schrag D, Weiser MR, Goodman KA, et al., Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial, J Clin Oncol, 2014;32:513–8.
  34. Ishii Y, Hasegawa H, Endo T, et al., Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer, Eur J Surg Oncol, 2010;36:1061–5.
  35. Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP, et al., Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control, Int J Radiat Oncol Biol Phys, 2014;88:822–8.
  36. Smith JD, Ruby JA, Goodman KA, et al., Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy, Ann Surg, 2012;256:965–72.
  37. Maas M, Beets-Tan RG, Lambregts DM, et al., Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer, J Clin Oncol, 2011;29:4633–40.
Keywords: Rectal cancer, radiation therapy, short course, long course, chemoradiation, neoadjuvant therapy